Galecto Inc (NAS:GLTO)

$ 0.6051 0.011 (1.81%) Market Cap: 16.41 Mil Enterprise Value: -10.61 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 38/100

Galecto Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Galecto Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Galecto Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Galecto Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Galecto Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Galecto Inc Corporate Call-Topline data From the Company Phase 1b/2a GULLIVER-2 Trial for liver cirrhosis Transcript
Nov 08, 2022
Galecto Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Galecto Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Galecto Inc at LifeSci Partners Immunology & Inflammation Symposium Transcript
May 11, 2022

Galecto Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2022 / 07:00PM GMT

Release Date Price: $2.1 (-4.11%)

Transcript

Russell Piekarsky

Jefferies - Analyst

Hi, everyone. This is Russ from the Jefferies team. Hope everyone's having good afternoon. I'm introducing Hans from Galecto.

Hans Schambye

Galecto, Inc. - CEO

Yes. Thanks a lot, Russ. So I'm here to talk about the Galecto. I will be making forward-looking statements, and you can find this on our website.

So in Galecto, we think we have some very unique assets. And we think we can use these to change the way that patients with fibrosis and cancer can live. So we have this very bold vision. And we believe it should be our mission of realizing the potential of modulating the galectin pathway with our inhibitors to really improve the way that cancer and fibrosis patients live.

We are a company focused on developing small-molecule therapeutics. We have two different targets that we're working on: LOXL2 and Galectin-3. These two proteins have both been shown to play central roles in the development of fibrosis and in cancer. And with our inhibitors, we believe we can change that.

We have four

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.